Get the Stockscreener App
2.28
1.94%
-0.045
Cervomed Inc stock is traded at $2.28, with a volume of 36,195.
It is down -1.94% in the last 24 hours and up +4.59% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$2.325
Open:
$2.35
24h Volume:
36,195
Relative Volume:
0.09
Market Cap:
$18.82M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-0.407
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-2.15%
1M Performance:
+4.59%
6M Performance:
-85.90%
1Y Performance:
-84.28%
1-Day Range:
$2.25
$2.36
1-Week Range:
$2.14
$2.38
52-Week Range:
$1.80
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.28 | 18.82M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CervoMed (NASDAQ:CRVO) Raised to Buy at D. Boral Capital - Armenian Reporter
Why CervoMed (CRVO) Is Advancing Today - Yahoo Canada Finance
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Boral Capital raises CervoMed stock to Buy, sets $10 target By Investing.com - Investing.com South Africa
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Boral Capital raises CervoMed stock to Buy, sets $10 target - Investing.com
How Are Things Looking For CervoMed Inc (NASDAQ: CRVO) For The Short Term? - Stocks Register
CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average PT from Brokerages - Defense World
Perigon Wealth Management LLC Makes New Investment in CervoMed Inc. (NASDAQ:CRVO) - Defense World
CervoMed Provides Update on Neflamapimod DLB Program as - GlobeNewswire
CervoMed reports progress in dementia drug trial - MSN
CervoMed Updates on Neflamapimod Trials for Dementia - TipRanks
CervoMed reports progress in dementia drug trial By Investing.com - Investing.com UK
Clinical Trial Setback: CervoMed's Dementia Drug Gets Second Chance with Enhanced Formula - StockTitan
CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewswire
Major Breakthrough in Lewy Body Dementia Treatment: CervoMed Reveals Game-Changing Clinical Data - StockTitan
CervoMed Inc. (NASDAQ:CRVO) Stock Holdings Lifted by Barclays PLC - Defense World
Roth MKM Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average Price Target from Analysts - Defense World
AWM Investment Company, Inc. Reduces Stake in CervoMed Inc - GuruFocus.com
CervoMed (STU:DP8) Momentum Rank : 8 (As of Jan. 11, 2025) - GuruFocus.com
Geode Capital Management LLC Raises Holdings in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Barclays PLC Acquires 5,919 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
Brookline Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
State Street Corp Boosts Stake in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $42.00 - Defense World
HC Wainwright Brokers Reduce Earnings Estimates for CervoMed - Defense World
Enhanced Cognition: Lewy body dementia phase II pumps stock - BioWorld Online
HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN
Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World
CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World
CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan
CervoMed's dementia drug fails mid-stage trial, shares slump - MSN
Chardan Capital Downgrades CervoMed (CRVO) - MSN
What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance
Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK
CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada
CervoMed shares rating downgraded after trial data disappoints - Investing.com
Jones Trading Downgrades CervoMed (CRVO) - MSN
CervoMed's dementia drug fails to meet mid-stage trial goals - MSN
CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com
CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch
CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD
Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):